eif4f nexus resistance anti-braf anti-mek cancer therapies 
brafv600-mutant tumours mechanisms resistance drugs target braf and/or mek kinases rely reactivation ras-raf-mek-erk mitogen-activated protein kinase mapk signal transduction pathway activation alternative pi k-akt-mtor pathway erk independent modulation caspase-dependent apoptotic cascade- three pathways converge regulate formation eif4f eukaryotic translation initiation complex binds methylguanylate cap mg end messenger rna thereby modulating translation specific mrnas show persistent formation eif4f complex comprising eif4e cap-binding protein eif4g scaffolding protein eif4a rna helicase associated resistance anti-braf anti-mek anti-braf plus anti-mek drug combinations brafv600-mutant melanoma colon thyroid cancer cell lines resistance treatment maintenance eif4f complex formation associated one three mechanisms: reactivation mapk signalling persistent erk-independent phosphorylation inhibitory eif4e-binding protein 4ebp1 increased pro-apoptotic bcl--modifying factor bmf-dependent degradation eif4g development situ method detect eif4e-eif4g interactions shows eif4f complex formation decreased tumours respond anti-braf therapy increased resistant metastases compared tumours treatment strikingly inhibiting eif4f complex either blocking eif4e-eif4g interaction targeting eif4a synergizes inhibiting brafv600 kill cancer cells eif4f appears indicator innate acquired resistance also promising therapeutic target combinations drugs targeting brafand/or mek eif4f may overcome resistance mechanisms arising brafv600-mutant cancers 
